致幻剂与精神分裂症:一把双刃剑
致幻剂在多种精神疾病中显示出有希望的效果,但至今尚无针对精神分裂症患者的现代临床试验,仅有一些上世纪50至60年代的半轶事性研究。这些旧研究报道了阴性症状和社会认知改善等有趣发现;作者从神经可塑性、连接性、免疫与TAARs系统、神经递质和神经营养因子等近期分子发现出发,指出致幻剂用于精神分裂症治疗具有较强生物学依据,并识别出以阴性症状为主的慢性患者亚群,提出涵盖极低剂量致幻剂(微剂量)的可能治疗策略,同时需仔细考虑安全性和可行性。
要点
- 至今尚无针对精神分裂症患者的致幻剂现代临床试验,仅有上世纪50至60年代的半轶事性研究。
- 旧研究报道了阴性症状和社会认知改善等有趣发现,但致幻剂的精神模拟特性可能加重阳性症状。
- 作者认为致幻剂用于精神分裂症治疗具有较强生物学依据,并提出以极低剂量(微剂量)为策略,需仔细考虑安全性和可行性。
核心结论
- 作者认为,尽管存在争议,致幻剂用于精神分裂症治疗具有较强生物学依据,并识别出以阴性症状为主的慢性患者亚群,提出涵盖极低剂量致幻剂(微剂量)的可能治疗策略,需仔细考虑安全性和可行性。
研究设计与样本
- 本文为观点性文章(perspective paper),未采用系统方法综述证据,原因是旧研究难以检索和解读。
主要发现
- 上世纪50至60年代的半轶事性研究报道了致幻剂对精神分裂症患者阴性症状和社会认知的改善。
- 致幻剂的精神模拟特性可能加重阳性症状,被视为值得注意的缺点。
- 致幻剂的作用机制与精神分裂症的致病基础部分重叠但方向相反。
局限性
- 至今尚无针对精神分裂症患者的致幻剂现代临床试验,仅有上世纪50至60年代的半轶事性研究。
- 本文未采用系统方法综述证据,原因是旧研究难以检索和解读。
- 致幻剂的精神模拟特性可能加重阳性症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psychedelics have shown promising effects in several psychiatric diseases as demonstrated by multiple clinical trials. However, no clinical experiments on patients with schizophrenia have been conducted up to date, except for some old semi-anecdotal studies mainly performed in the time-span '50s-'60s. Notably, these studies reported interesting findings, particularly on the improvement of negative symptoms and social cognition. With no doubts the lack of modern clinical studies is due to the psychomimetic properties of psychedelics, a noteworthy downside that could worsen positive symptoms. However, a rapidly increasing body of evidence has suggested that the mechanisms of action of such compounds partially overlaps with the pathogenic underpinnings of schizophrenia but in an opposite way. These findings suggest that, despite being a controversial issue, the use of psychedelics in the treatment of schizophrenia would be based on a strong biological rationale. Therefore, the aim of our perspective paper is to provide a background on the old experiments with psychedelics performed on patients with schizophrenia, interpreting them in the light of recent molecular findings on their ability to induce neuroplasticity and modulate connectivity, the immune and TAARs systems, neurotransmitters, and neurotropic factors. No systematic approach was adopted in reviewing the evidence given the difficulty to retrieve and interpret old findings. Interestingly, we identified a therapeutic potential of psychedelics in schizophrenia adopting a critical point of view, particularly on negative symptoms and social cognition, and we summarized all the relevant findings. We also identified an eligible subpopulation of chronic patients predominantly burdened by negative symptoms, outlining possible therapeutic strategies which encompass very low doses of psychedelics (microdosing), carefully considering safety and feasibility, to pave the way to future clinical trials.
引用
- Sapienza J, Martini F, Comai S, et al. Psychedelics and schizophrenia: a double-edged sword. Mol Psychiatry. 2024. PMID: 39294303. doi:10.1038/s41380-024-02743-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。